Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Costco Wholesale Corporation (COST) Price & Performance

AbCellera Biologics IncTrade
Costco Wholesale CorporationTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Costco Wholesale Corporation — how do they compare? AbCellera Biologics Inc trades at $9.06 (market cap $2.85B), while Costco Wholesale Corporation trades at $943 (market cap $422.52B). The key difference: Costco Wholesale Corporation is far larger — about 148.3× AbCellera Biologics Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLCOST
Market Cap
$2.85B$422.52B
Sector
HealthConsumer Staples
52-Week High
$9.76$1.09K
52-Week Low
$2.78$849.63
Enterprise Value
$2.45B$410.66B
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Costco Wholesale Corporation

Costco (COST) trades at $952.75, up 0.52% with neutral technical signals. The company shows steady revenue growth, reaching $275.24B in 2025, and maintains strong profitability with a 3.01% net margin. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst sentiment remains bullish with 65.52% buy ratings and a $1,120 consensus price target, while institutional buying activity continues.

Costco's outlook is positive due to membership fee growth and expansion, though high valuation multiples (P/E 47.93) pose risks. Key opportunities include consistent cash flow generation and market share gains, while risks involve competitive pressures and economic sensitivity. The stock offers long-term growth potential but requires monitoring of valuation metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Costco Wholesale Corporation

The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet

Read more on COST